J2KBIO Co., Ltd. (KOSDAQ:420570)
South Korea · Delayed Price · Currency is KRW 9,480.00
-90.00 (-0.94%)
Last updated: Sep 16, 2025, 12:54 PM KST
J2KBIO Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Operating Revenue | 29,074 | 33,129 | 28,472 | 16,032 | 14,219 | 13,858 |
Other Revenue | -0 | -0 | - | -0 | - | - |
| 29,074 | 33,129 | 28,472 | 16,032 | 14,219 | 13,858 | |
Revenue Growth (YoY) | -19.06% | 16.36% | 77.60% | 12.75% | 2.60% | - |
Cost of Revenue | 18,323 | 20,472 | 16,970 | 8,974 | 8,289 | 9,188 |
Gross Profit | 10,751 | 12,657 | 11,502 | 7,058 | 5,929 | 4,670 |
Selling, General & Admin | 6,843 | 6,483 | 4,233 | 3,468 | 2,905 | 2,358 |
Research & Development | 2,131 | 1,902 | 1,217 | 877.86 | 778.41 | 760.51 |
Operating Expenses | 9,844 | 9,031 | 5,896 | 4,734 | 4,055 | 3,544 |
Operating Income | 907.1 | 3,626 | 5,607 | 2,324 | 1,874 | 1,126 |
Interest Expense | -34.91 | -95.78 | -176.48 | -258.28 | -202.13 | -115.92 |
Interest & Investment Income | 203.86 | 147.2 | 54.1 | 13.38 | 5.69 | 4.24 |
Currency Exchange Gain (Loss) | -13.46 | 11.08 | 7.4 | 15.35 | 3.21 | -5.8 |
Other Non Operating Income (Expenses) | -55.31 | -5,133 | 50.59 | 193.11 | 12.54 | 467.38 |
EBT Excluding Unusual Items | 1,007 | -1,444 | 5,542 | 2,287 | 1,693 | 1,476 |
Gain (Loss) on Sale of Investments | 43.12 | 85.7 | 36.58 | -64.4 | - | - |
Gain (Loss) on Sale of Assets | -2.09 | -2.09 | 0.11 | -39.95 | - | - |
Asset Writedown | -7.98 | - | -6.74 | - | -99.33 | - |
Pretax Income | 1,040 | -1,361 | 5,572 | 2,183 | 1,594 | 1,476 |
Income Tax Expense | -118.37 | 310.69 | 774.03 | 118.65 | -29.4 | 0.59 |
Earnings From Continuing Operations | 1,159 | -1,671 | 4,798 | 2,064 | 1,623 | 1,475 |
Minority Interest in Earnings | - | 18.77 | 45.52 | 21.85 | - | - |
Net Income | 1,159 | -1,653 | 4,844 | 2,086 | 1,623 | 1,475 |
Net Income to Common | 1,159 | -1,653 | 4,844 | 2,086 | 1,623 | 1,475 |
Net Income Growth | 14.80% | - | 132.18% | 28.53% | 10.01% | - |
Shares Outstanding (Basic) | 6 | 6 | 5 | 5 | 0 | 0 |
Shares Outstanding (Diluted) | 6 | 6 | 5 | 5 | 0 | 0 |
Shares Change (YoY) | 10.17% | 9.44% | - | 8051.19% | - | - |
EPS (Basic) | 202.05 | -299.50 | 1000.99 | 448.24 | 26241.41 | 23854.33 |
EPS (Diluted) | 202.05 | -299.50 | 978.27 | 414.44 | 26241.41 | 23854.33 |
EPS Growth | 4.05% | - | 136.05% | -98.42% | 10.01% | - |
Free Cash Flow | -1,016 | 23.37 | 1,916 | 1,328 | 1,203 | -1,013 |
Free Cash Flow Per Share | -177.11 | 4.24 | 380.01 | 263.40 | 19442.01 | -16377.58 |
Dividend Per Share | 200.000 | 200.000 | - | - | - | - |
Gross Margin | 36.98% | 38.20% | 40.40% | 44.02% | 41.70% | 33.70% |
Operating Margin | 3.12% | 10.95% | 19.69% | 14.49% | 13.18% | 8.13% |
Profit Margin | 3.98% | -4.99% | 17.01% | 13.01% | 11.42% | 10.65% |
Free Cash Flow Margin | -3.49% | 0.07% | 6.73% | 8.28% | 8.46% | -7.31% |
EBITDA | 2,294 | 4,744 | 6,241 | 2,881 | 2,380 | 1,461 |
EBITDA Margin | 7.89% | 14.32% | 21.92% | 17.97% | 16.74% | 10.54% |
D&A For EBITDA | 1,387 | 1,118 | 634.44 | 556.88 | 506.57 | 334.45 |
EBIT | 907.1 | 3,626 | 5,607 | 2,324 | 1,874 | 1,126 |
EBIT Margin | 3.12% | 10.95% | 19.69% | 14.49% | 13.18% | 8.13% |
Effective Tax Rate | - | - | 13.89% | 5.44% | - | 0.04% |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.